IDentif.AI-Optimized Drug Combinations to Restore COVID-19 Antibody Therapy Potency

A research document describes the use of the IDentif.AI platform to identify synergistic drug combinations that restore the effectiveness of the monoclonal antibody sotrovimab against the XBB SARS-CoV-2 variant. The study, authored by Peter Wang, was posted on figshare in June 2026. It reports that identified combinations reduced the in vitro EC50 of sotrovimab by up to 7-fold.

Use Cases

• Training AI models for drug combination optimization based on the described IDentif.AI platform methodology.
• Analyzing synergistic interactions between monoclonal antibodies and small molecules like EIDD-1931 or GS-441524.
• Studying resistance mechanisms of SARS-CoV-2 variants, specifically the XBB subvariant of Omicron.
• Designing in vitro experiments to validate AI-predicted drug combination efficacy.

Strengths

• The document provides a specific, quantitative result, reporting a 7-fold reduction in EC50.
• It is associated with a concrete AI platform (IDentif.AI) and a specific therapeutic goal.
• The dataset is openly licensed under CC-BY-4.0.

Limitations

• The primary data file is a 1.1 MB DOCX document, not a structured data table; column-level documentation is absent.
• Row count is unknown, which may limit suitability assessment for quantitative analysis.
• The description metadata is limited to the research article's sections; actual experimental data quality requires manual inspection after download.

Provenance

Source

figshare, author Peter Wang.

Collection Method

Likely contains results from an AI-driven experimental optimization platform (IDentif.AI) applied to in vitro drug testing.

Time Range

The research context involves the XBB variant, which was predominantly spreading worldwide in 2023.

Freshness

Last updated 2026-06-02 05:26:41; freshness should be verified.